Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis

about

Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis

Item

http://www.wikidata.org/entity/Q41310328

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Using Genomic Information to G ...... A Cost-Effectiveness Analysis

@en

type

Item

label

Using Genomic Information to G ...... A Cost-Effectiveness Analysis

@en

prefLabel

Using Genomic Information to G ...... A Cost-Effectiveness Analysis

@en

P1476

Using Genomic Information to G ...... A Cost-Effectiveness Analysis

@en

P2093

Anna Schuh

http://www.w3.org/2001/XMLSchema#string

Pauline Robbe

http://www.w3.org/2001/XMLSchema#string

Ruth Clifford

http://www.w3.org/2001/XMLSchema#string

Sarah Wordsworth

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia

Q26995732

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

TP53 mutation and survival in chronic lymphocytic leukemia.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

The impact of next-generation sequencing technology on genetics

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

P2888

s40273-017-0519-z

P304

845-858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-017-0519-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James Buchanan

Samantha J.L. Knight

Jenny Taylor

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090930975

http://www.w3.org/2001/XMLSchema#string

P698

28762015

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

5548825

http://www.w3.org/2001/XMLSchema#string